• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.

作者信息

Yuan Xianggui, Xie Yaping, Xu Nengwen, Liu Hui, Chen Panpan, Zhao Aiqi, Liang Yun, Qian Wenbin

机构信息

Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 310009.

Department of Hematology, the Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China, 310006.

出版信息

Haematologica. 2024 Jun 1;109(6):2005-2009. doi: 10.3324/haematol.2023.284834.

DOI:10.3324/haematol.2023.284834
PMID:38356447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11141638/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c31/11141638/2869273e3a08/1092005.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c31/11141638/2869273e3a08/1092005.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c31/11141638/2869273e3a08/1092005.fig1.jpg

相似文献

1
Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.来那度胺、利妥昔单抗和甲氨蝶呤对新诊断的原发性中枢神经系统淋巴瘤有效。
Haematologica. 2024 Jun 1;109(6):2005-2009. doi: 10.3324/haematol.2023.284834.
2
[Lenalidomide, rituximab and dexamethasone for the treatment of recurrent/refractory or elderly newly diagnosed patients with primary central nervous system lymphoma: 5 cases report and literature review].来那度胺、利妥昔单抗和地塞米松治疗复发/难治性或老年新诊断的原发性中枢神经系统淋巴瘤患者：5例报告及文献复习
Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14;40(12):1047-1049. doi: 10.3760/cma.j.issn.0253-2727.2019.12.016.
3
Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma-a single-center retrospective study.奥布替尼联合利妥昔单抗和来那度胺治疗低KPS评分老年初诊原发性中枢神经系统淋巴瘤患者的有效性和安全性——一项单中心回顾性研究
Neurol Sci. 2024 Jun;45(6):2931-2934. doi: 10.1007/s10072-024-07348-4. Epub 2024 Feb 7.
4
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.甲氨蝶呤-阿糖胞苷-地塞米松联合化疗联合或不联合利妥昔单抗治疗原发性中枢神经系统淋巴瘤患者。
Oncotarget. 2017 Jul 25;8(30):49156-49164. doi: 10.18632/oncotarget.17101.
5
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.在免疫功能正常的新诊断原发性中枢神经系统淋巴瘤患者中，利妥昔单抗、甲氨蝶呤、替莫唑胺诱导治疗后，高剂量依托泊苷联合阿糖胞苷作为巩固治疗的疗效和安全性。
Haematologica. 2018 Jul;103(7):e296-e299. doi: 10.3324/haematol.2017.185843. Epub 2018 Feb 22.
6
Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.R-MPV 或大剂量甲氨蝶呤单药治疗原发性中枢神经系统淋巴瘤的连续单机构病例系列。
Jpn J Clin Oncol. 2020 Sep 5;50(9):999-1008. doi: 10.1093/jjco/hyaa073.
7
The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first-line methotrexate treatment: A retrospective study.一线甲氨蝶呤治疗后原发中枢神经系统淋巴瘤采用来那度胺维持治疗的作用：一项回顾性研究。
Cancer Med. 2024 May;13(9):e7193. doi: 10.1002/cam4.7193.
8
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.利妥昔单抗、甲氨蝶呤、丙卡巴肼、长春新碱及强化阿糖胞苷巩固治疗老年原发性中枢神经系统淋巴瘤（PCNSL）：一项LOC网络研究
J Neurooncol. 2017 Jun;133(2):315-320. doi: 10.1007/s11060-017-2435-7. Epub 2017 Apr 21.
9
Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.利妥昔单抗在原发性中枢神经系统淋巴瘤患者治疗中的作用：捷克淋巴瘤研究组登记处的回顾性分析
Leuk Lymphoma. 2016 Dec;57(12):2777-2783. doi: 10.3109/10428194.2016.1167203. Epub 2016 Apr 18.
10
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma.来那度胺、甲氨蝶呤、亚叶酸钙、阿糖胞苷和利妥昔单抗（LeMLAR）用于复发或难治性弥漫性大B细胞淋巴瘤的I/II期试验
Blood Cancer J. 2021 May 17;11(5):95. doi: 10.1038/s41408-021-00485-5.

引用本文的文献

1
Efficacy and safety of the R2-MTX regimen in primary central nervous system lymphoma (PCNSL): a single-center retrospective analysis.R2-MTX方案治疗原发性中枢神经系统淋巴瘤（PCNSL）的疗效与安全性：一项单中心回顾性分析
J Cancer Res Clin Oncol. 2025 May 22;151(5):173. doi: 10.1007/s00432-025-06205-x.
2
In the era of targeted therapy and immunotherapy: advances in the treatment of large B-cell lymphoma of immune-privileged sites.在靶向治疗和免疫治疗时代：免疫豁免部位大B细胞淋巴瘤的治疗进展
Front Immunol. 2025 Apr 1;16:1547377. doi: 10.3389/fimmu.2025.1547377. eCollection 2025.